Here’s Why GW Pharmaceuticals Dropped 12% in August

What happened

Shares of GW Pharmaceuticals (NASDAQ: GWPH) dropped 12.2% in August, according to data provided by S&P Global Market Intelligence, after the company posted fairly solid second-quarter results.

So what

Sales of Epidiolex, a cannabidiol (CBD) drug derived from marijuana, more than doubled from the first quarter to the second quarter with over 12,000 patients having received the drug and a "vast majority" remaining on the therapy, according to the company.

On the bottom line, GW Pharmaceuticals posted a profit of $0.21 per share, although that was entirely due to selling a Rare Pediatric Priority Review Voucher. If a company doesn't need the voucher, which can be turned in for a faster FDA review, it can be sold -- as GW Pharmaceuticals did for a little over $104 million.

The company's operating loss improved to $29.3 million from $81.4 million in the year-ago quarter.

Overall, this seems to be a sell-the-news issue for the cannabis-focused biotech. It took about a week to erase the post-earnings gains, and then it was downhill from there. The fact that GW Pharmaceuticals was one of the best-performing cannabis stocks on the market so far in 2019 probably contributed to the decline. Even after the rough month, it's still up over 45% for the year.

Marijuana growing in a greenhouse

Image source: Getty Images.

Now what

With growth likely to continue, this move could be a good opportunity for investors to buy GW Pharmaceuticals on the cheap(er).

In July, the company gained a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for Epidiolex as a treatment for Lennox-Gastaut syndrome and Dravet syndrome. In the EU, the drug will go by the brand name Epidyolex.

The European Commission should give the rubber-stamp final approval in the next few weeks. GW Pharmaceuticals will be able to launch in some European countries quickly, but many countries will require negotiations with national healthcare organizations before the company can start benefiting from the additional approval.

10 stocks we like better than GW Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and GW Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of June 1, 2019


Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More